Overview

Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the potential clinical benefit of prophylactic cytomegalovirus (CMV)-specific adoptive cellular therapy following T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) for reducing recurrent CMV reactivation.
Phase:
Phase 3
Details
Lead Sponsor:
Cell Medica Ltd
Collaborators:
BioAnaLab
Commitum AB
EMAS Pharma
Wellcome Trust
Treatments:
Antiviral Agents